Investegate announcements from F. Hoffmann-La Roche Ltd, New data for Roche’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA)
Long-term efficacy data from the pivotal SUNFISH study confirm increases in motor function are sustained at three years while adverse events decreased over the same periodPart 2 of SUNFISH showed Evrysdi
FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy– RAINBOWFISH study interim results showed that after treatment with Evrysdi pre-symptomatic infants with spinal muscular atrophy achieved same motor milestones as healthy infants –S.